Jason J. Luke

Also affiliated with UPMC Hillman Cancer Center, University of Pittsburgh Medical Center

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 57 papers. Top paper: “Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma”.

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

Cancer Cell(2021)10.1016/j.ccell.2020.11.015

N/A

1.9DataRank · unranked

53 citations

Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodriguez, Petra Ross-Macdonald, Megan Wind-Rotolo +31 more

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

Cancer Cell(2024)10.1016/j.ccell.2024.10.007

N/A

1.3DataRank · unranked

59 citations

Robert M. Morrison, Amiran Dzutsev, Arivarasan Karunamurthy, Joë-Marc Chauvin, F. Amatore +48 more

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

Science(2018)10.1126/science.aao3290

N/A

1.2DataRank · unranked

2947 citations

Jessica Fessler, Riyue Bao, Tara Chongsuwat, Yuanyuan Zha, Maria-Luisa Alegre +4 more

Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases

Journal of Clinical Investigation(2023)10.1172/jci162260

N/A

1.1DataRank · unranked

22 citations

Benjamin E. Onderdonk, Rebekah Dadey, Jared H. Hara, Lilit Karapetyan, Yuanyuan Zha +8 more

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Melanoma Research(2020)10.1097/cmr.0000000000000701

N/A

0.757DataRank · unranked

14 citations

Oliver Surriga, Daniel J. Olson, Jacob B. Allred, Carrie Strand, Yuanyuan Zha +11 more

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008668

N/A

0.742DataRank · unranked

29 citations

Tobias A.W. Holderried, Jason J. Luke, Van K. Morris, Winfried Alsdorf, Katrin Wetzko +27 more

Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2824

N/A

0.656DataRank · unranked

22 citations

Randy F. Sweis, J. Randolph Hecht, Reva Schneider, Mark N. Stein, Talia Golan +7 more

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

JCO Precision Oncology(2023)10.1200/po.22.00421

N/A

0.656DataRank · unranked

16 citations

Yael Flamand, Melissa Wilson, Jason J. Luke, Hussein A. Tawbi, Fangxin Hong +19 more

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0339

N/A

0.587DataRank · unranked

49 citations

Roberta Zappasodi, Hong Wang, Girish S. Naik, Takami Sato, Todd M. Bauer +13 more

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations

The Oncologist(2025)10.1093/oncolo/oyaf362

N/A

0.307DataRank · unranked

6 citations

Mark Jelinek, Arjun Singh, Brian R. Isett, Erica S. Myers, Steven J. Mullett +23 more

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations

medRxiv(2025)10.1101/2025.07.19.25331848

N/A

0.279DataRank · unranked

5 citations

Mark Jelinek, Arjun Singh, Brian R. Isett, Erica S. Myers, Steven J. Mullett +23 more

Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-3312

N/A

0DataRank · unranked

5 citations

Jason J. Luke, Lilit Karapetyan

Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-3022

N/A

0DataRank · unranked

4 citations

Riyue Bao, Jason J. Luke, Ryan C. Augustin

Autoantibodies as Predictors for Clinical Outcome and Toxicity for Immunotherapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1664

N/A

0DataRank · unranked

2 citations

Jason J. Luke, Jessica C. Hassel

Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9507

N/A

0DataRank · unranked

17 citations

Julie E. Stein, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Nikhil I. Khushalani +13 more

605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0605

N/A

0DataRank · unranked

4 citations

Joë-Marc Chauvin, Robert Morrison, Yulong Bai, Jie Sun, Hong Wang +22 more

Th2 cells are associated with recurrence following radiation in human papillomavirus negative head and neck cancer.

Research Square(2022)10.21203/rs.3.rs-1537302/v1

N/A

0DataRank · unranked

1 citations

Riyue Bao, Phillip M. Pifer, David Molkentine, Jessica M. Molkentine, Andrew Hefner +9 more

Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma

Research Square(2022)10.21203/rs.3.rs-2235839/v1

N/A

0DataRank · unranked

1 citations

Arivarasan Karunamurthy, Joë-Marc Chauvin, Robert M. Morrison, Yulong Bai, Jie Sun +40 more

Th2 cells are associated with tumor recurrence following radiation.

Research Square(2022)10.21203/rs.3.rs-1537302/v2

N/A

0DataRank · unranked

0 citations

Riyue Bao, Phillip M. Pifer, David Molkentine, Jessica M. Molkentine, Andrew Hefner +9 more

Targeting Cbl-b in cancer immunotherapy

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-006007

N/A

0DataRank · unranked

93 citations

Riyue Bao, Jason J. Luke, Ryan C. Augustin

Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad118

N/A

0DataRank · unranked

25 citations

Uzoma K. Iheagwara, Adam C. Olson, Steven J. Chmura, Heath K Skinner, Jason J. Luke +1 more

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007567

N/A

0DataRank · unranked

17 citations

Sarah Newman, Aofei Li, Marion Joy, Maureen A. Lyons, Mary P Pham +11 more

Myeloid Maturity: ATRA to Enhance Anti–PD-1?

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3652

N/A

0DataRank · unranked

13 citations

Jason J. Luke, Daniel J. Olson

Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition

European Journal of Cancer(2023)10.1016/j.ejca.2023.05.011

N/A

0DataRank · unranked

7 citations

Vylyny Chat, Leah Morales, Danny Simpson, Kelsey R. Monson, Elisheva Cohen +12 more

Top advances of the year: Melanoma

Cancer(2023)10.1002/cncr.34590

N/A

0DataRank · unranked

5 citations

Jason J. Luke, Ryan C. Augustin

PD-1 Monotherapy Reigns Supreme in Adjuvant Melanoma…But for How Long?

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1194

N/A

0DataRank · unranked

4 citations

Jason J. Luke, Ryan C. Augustin

Platelet STING agonism and venous thrombosis: translational implications for improved disease outcomes

Journal of Leukocyte Biology(2023)10.1093/jleuko/qiad073

N/A

0DataRank · unranked

1 citations

Jason J. Luke, Walter J. Storkus, J Filderman

Potential of circulating tumor DNA to refine immunotherapy

Cancer(2023)10.1002/cncr.34714

N/A

0DataRank · unranked

1 citations

Jason J. Luke, Rebecca Lee

Tumor cell p38 inhibition to overcome immunotherapy resistance

Research Square(2023)10.21203/rs.3.rs-3183496/v1

N/A

0DataRank · unranked

5 citations

Rebekah Dadey, Ryan C. Augustin, Sarah Newman, Krishna B. Singh, Rose Doerfler +26 more

NETosis Impact on Tumor Biology, Radiation, and Systemic Therapy Resistance

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1363

N/A

0DataRank · unranked

17 citations

Jason J. Luke, Yvonne M. Mowery

Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-22-2241

N/A

0DataRank · unranked

7 citations

Wesley L. Cai, Jason J. Luke, Riyue Bao, Ryan C. Augustin

Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma

American Journal of Clinical Dermatology(2024)10.1007/s40257-024-00852-5

N/A

0DataRank · unranked

7 citations

Jason J. Luke, Ryan C. Augustin

Th2 Cells Are Associated with Tumor Recurrence Following Radiation

Cancers(2024)10.3390/cancers16081586

N/A

0DataRank · unranked

2 citations

Riyue Bao, Phillip M. Pifer, David Molkentine, Jessica M. Molkentine, Andrew Hefner +9 more

Top advances of the year: Melanoma

Cancer(2024)10.1002/cncr.35354

N/A

0DataRank · unranked

2 citations

Jason J. Luke, Muhammad Adnan Khattak

Unraveling the Therapeutic Benefit of Sequenced Chemo-immunotherapy

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3736

N/A

0DataRank · unranked

2 citations

Jason J. Luke, Paolo Vignali

Jeffrey S Weber, MD, PhD (1952–2024): in memoriam to discovery, friendship and family

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-010464

N/A

0DataRank · unranked

1 citations

Omid Hamid, Bernard A. Fox, Paolo A. Ascierto, Iman Osman, James J. Mulé +3 more

The emergence of neoadjuvant immune‐ over BRAF therapy in melanoma

Cancer(2024)10.1002/cncr.35490

N/A

0DataRank · unranked

0 citations

Jason J. Luke, Elisa A. Rozeman

Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers

Research Square(2024)10.21203/rs.3.rs-5494074/v1

N/A

0DataRank · unranked

0 citations

Brandon M. Lehrich, Evan R. Delgado, Tyler M. Yasaka, Silvia Liu, Catherine Cao +29 more

Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers

Nature Communications(2025)10.1038/s41467-025-60457-2

N/A

0DataRank · unranked

31 citations

Evan R. Delgado, Tyler M. Yasaka, Silvia Liu, Catherine Cao, Y. Liu +30 more

Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-011537

N/A

0DataRank · unranked

11 citations

Ruxuan Li, Jake Griner, Jie Chen, Arjun Singh, Brian R. Isett +12 more

Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancer

Oral Oncology(2025)10.1016/j.oraloncology.2025.107742

N/A

0DataRank · unranked

11 citations

Jie Chen, Carl Kim, Joshua D. Smith, Micah Harris, Krishna B. Singh +24 more

Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2024-009568

N/A

0DataRank · unranked

7 citations

Zane Gray, Rebekah Dadey, Şerafettin Zenkin, Nasim Batavani, Sarah Newman +19 more

Integrating Artificial Intelligence-Driven Digital Pathology and Genomics to Establish Patient-Derived Organoids as a Novel Alternative Model for Drug Response in Head and Neck Cancer

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.06.24.660824

N/A

0DataRank · unranked

2 citations

Jie Chen, Carl Kim, Joshua D. Smith, Micah Harris, Krishna B. Singh +24 more

Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma

medRxiv(2025)10.1101/2025.11.04.25339499

N/A

0DataRank · unranked

2 citations

Anthony R. Cillo, Shuaichao Wang, Arivarasan Karunamurthy, Ryan Massa, Anjali Rohatgi +16 more

Multiregional CT Features Improve Prediction of Immunotherapy Response in Advanced Melanoma

medRxiv(2025)10.1101/2025.10.26.25338837

N/A

0DataRank · unranked

0 citations

Jatin Singh, Drew E. Hurd, Tong Yu, Xin Meng, Madison Nguyen +9 more

1340 Lead-in therapy targeting PD1 and/or LAG3 distinguishes differential impacts upon the immune response in first-line treatment of metastatic melanoma

(2025)10.1136/jitc-2025-sitc2025.1340

N/A

0DataRank · unranked

0 citations

Anthony R. Cillo, Shuaichao Wang, Arivarasan Karunamurthy, Ryan Massa, Anjali Rohatgi +15 more

Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes

Frontiers in Immunology(2023)10.3389/fimmu.2023.1171978

N/A

0DataRank · unranked

10 citations

Hassan Abushukair, Aofei Li, Andrew Knight, Ayah Nedal Al Bzour, Ian MacFawn +16 more

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

Cancer Cell(2020)10.1016/j.ccell.2020.08.005

N/A

0DataRank · unranked

389 citations

Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodríguez, Petra Ross‐Macdonald, Megan Wind‐Rotolo +31 more

Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-1321

N/A

0DataRank · unranked

137 citations

Jason J. Luke, Christopher Garris

Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes

Science Immunology(2020)10.1126/sciimmunol.aaz3199

N/A

0DataRank · unranked

50 citations

Shidan Wang, Lin Xu, Qinbo Zhou, Nirmish Singla, Jianjun Gao +9 more

Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer

Therapeutic Advances in Medical Oncology(2020)10.1177/1758835920913798

N/A

0DataRank · unranked

50 citations

Selene Meza‐Perez, Angelina I. Londoño, Whitney N. Goldsberry, Ashwini A. Katre, Jonathan Boone +16 more

Tumor Neoantigenicity Assessment with CSiN Score Incorporates Clonality and Immunogenicity to Predict Immunotherapy Outcomes

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.01.23.917625

N/A

0DataRank · unranked

5 citations

Shidan Wang, Lin Xu, Qinbo Zhou, Nirmish Singla, Jianjun Gao +8 more

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1963

N/A

0DataRank · unranked

369 citations

Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H.I. Andtbacka, Matthew Ingham +11 more

Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002417

N/A

0DataRank · unranked

46 citations

Stefani Spranger, Kyle M. Hernandez, Yuanyuan Zha, Peter Pytel, Jason J. Luke +5 more

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers

Cancers(2021)10.3390/cancers13215415

N/A

0DataRank · unranked

30 citations

Arjun Vasant Balar, Jason J. Luke, Brian Labadie

Ipilimumab Combination Dosing: Less is More

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2406

N/A

0DataRank · unranked

8 citations

Jason J. Luke, Max Jameson-Lee

Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2277

N/A

0DataRank · unranked

8 citations

Jason J. Luke, Valsamo Anagnostou